

## Important Contact Information

Name of Specialist

Phone

After-hours Phone

My Name

My Phone

Name of Emergency Contact

Emergency Contact (Phone)

NX-IL-DST-CRD-210001

The card and its content were approved by the Ministry of Health on Oct 2021

## Patient Card

### JEMPERLI (dostarlimab)

**Important safety information to lower the risk of immune-related side effects**

JEMPERLI may cause side effects that can sometimes become serious or life-threatening and can lead to death. Side effects may happen at any time during treatment or after treatment has ended. You may experience side effects in more than one body part at the same time.

Contact your specialist immediately if you have any of the listed symptoms or any symptoms not listed on this card, or if symptoms worsen. **Prompt medical treatment may keep the problem from becoming more serious.** Your doctor may provide other medicines to treat your symptoms, withhold the next dose of JEMPERLI, or stop treatment.

For more information, consult the Package Leaflet (PL) at <https://data.health.gov.il/drugs/index.html#!/byDrug> or call your doctor

### IMPORTANT

- Do not attempt to diagnose or treat side effects yourself
- **Keep this card with you at all times**, including when travelling, going to the Accident and Emergency department, or seeing another doctor
- Keep this card for at least 4 months after the last dose of JEMPERLI
- Notify any health care professional you see that you are being treated with JEMPERLI and show them this card

## Call your Oncology Care Team if you have any of these signs or symptoms, any others, or if they get worse.

### Lungs

- Shortness of breath
- Chest pain
- New or worse cough

### Intestines

- Diarrhoea or more frequent bowel movements
- Black, tarry, sticky stool; blood or mucus in stools
- Severe stomach pain or tenderness
- Feeling or being sick (nausea or vomiting)

### Liver

- Feeling or being sick (nausea or vomiting)
- Loss of appetite
- Pain on right side of the stomach
- Yellowing skin or whites of eyes
- Dark-coloured urine
- Bleeding or bruising more easily than normal

### Hormone glands

- Rapid heartbeat
- Weight loss or gain
- Increased sweating
- Hair loss
- Feeling cold
- Constipation
- Abdominal pain
- Deeper voice
- Muscle aches
- Dizziness or fainting
- Persisting or unusual headache

### Kidneys

- Changes in urine amount or colour
- Swelling ankles
- Loss of appetite
- Blood in urine

### Skin

- Rash, itching, peeling or skin sores
- Ulcers in the mouth, nose, throat or genital area

### Eyes

- Changes in eyesight

### Other organs

- Severe or persistent muscle or joint pains
- Severe muscle weakness
- Swollen or cold hands or feet

These are not the only side effects of JEMPERLI. If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in the package leaflet.

You can also report side effects directly via the Ministry of Health (MOH) by clicking on the link "reporting adverse event due to drug treatment" which can be found in the MOH website ([www.health.gov.il](http://www.health.gov.il)) or click on the link <https://sideeffects.health.gov.il>.

In addition, please report to GSK at email address [il.safety@gsk.com](mailto:il.safety@gsk.com).

By reporting side effects, you can help provide more information on the safety of this medicine.

## Important Information for Health Care Providers

This patient is being treated with JEMPERLI which can cause immune-related adverse reactions that may appear any time during treatment or after treatment. Immune-related adverse reactions may occur in any organ or tissue and may affect more than one body system simultaneously. Assess patients for signs and symptoms of immune-related adverse reactions including but not limited to those listed on this card. Early diagnosis and appropriate management are essential to minimise any consequences of immune-related adverse reactions.

For suspected immune-related adverse reactions, ensure adequate evaluation to confirm aetiology or exclude other causes. Based on the severity of the adverse reaction, JEMPERLI should be withheld or permanently discontinued and corticosteroids or other appropriate therapy administered.

Specific guidelines for managing immune-related adverse reactions are available in the Summary of Product Characteristics for JEMPERLI.

Consultation with an oncologist or other medical specialist may be helpful for the management of immune-related adverse reactions.

Please consult the Summary of Product Characteristics for JEMPERLI at <https://data.health.gov.il/drugs/index.html#!/byDrug> or call your doctor for more information